Dr. Richard Horowitz reports the first published case of reversing P-tau 217, the most sensitive and specific Alzheimer's biomarker, in a live patient using a nine-week oral dapsone combination protocol, lowering it by 63% compared to the 23% reduction seen over six to seven years with anti-amyloid drugs like lecanemab. Author of the upcoming book Ending Chronic Illness, Dr. Horowitz breaks down his 16-point MSIDS model linking chronic Lyme disease, Bartonella, mold toxicity, and biofilm-persistent infections to Alzheimer's, long COVID, chronic fatigue syndrome, fibromyalgia, and autoimmune disease. He and Dr. Dean Mitchell also cover how to take a proper differential diagnosis history, why dapsone blocks the NLRP3 inflammasome pathway driving brain inflammation, and practical tick-bite prevention with picaridin and permethrin-treated clothing.
Social Media:LinkedIn:
linkedin.com/in/richard-horowitz-b4634012Facebook:
facebook.com/drrichardhorowitzInstagram: @drrichardhorowitz
Websites:Book (Ending Chronic Illness):
cangetbetter.com/ending-chronic-illnessPrimary site:
cangetbetter.comResources / Book Links:Medical Detective Substack:
medicaldetective.substack.comDapsone documentary (2024):
DrTalks: Discover Healing 18 - Dapsone TestimonialsContact Dr. Mitchell:Email: care@mitchellmedicalgroup.com
WebsiteInstagramYouTubeFacebookLinkedInBook:
Conquering CandidaImmunoLytics - code SmartestDoc, 5% off
Apollo Neuro - code SMARTMD